Saccharomyces cerevisiae (brewer's or baker's yeast) is an extremely rare cause of fungal sepsis. It is an asporogenous yeast that is used in the production of baked goods, beer, wine, and occasionally found in health foods. It colonizes the human respiratory tract, gastrointestinal tract, urinary tract, and vagina. Severe immunosuppression, prolonged hospitalization, prior antibiotic therapy, and prosthetic cardiac valves are the settings where Saccharomyces infection has been observed.
1
S. cerevisiae has been classified within the yeast species as a new or emerging pathogen since 1990. Increasing case reports in the medical literature are an indication of emerging yeast infections. 2, 3 In this report we will describe a 35-week-old neonate who had feeding intolerance and frequent episodes of presumed sepsis treated empirically with vancomycin, cefotaxime, and gentamicin. The patient had no other underlying problems, or central venous catheters.
CASE REPORT
This is a 1409-g, small for gestational age, 34-week-old female born by vaginal delivery. The mother had prenatal care and was diagnosed with pyelonephritis and pre-eclampsia just before delivery. The mother was on Procardia for chronic hypertension and received aztreonam 12 hours before the delivery. The delivery was uneventful and Apgars were 7 at 1 minute and 8 at 5 minutes. The patient was admitted to the intensive care unit with mild respiratory distress diagnosed as transient tachypnea of the newborn. This resolved within the first day of life and required no ventilatory management. The rest of the physical exam was within normal limits. The patient was started on ampicillin and claforan secondary to suspected sepsis related to prematurity and respiratory distress. During the following days the patient remained asymptomatic until enteral feeds were started on the fourth day of life. The patient at that point had feeding intolerance manifested by abdominal distention and dilated loops of bowel on a KUB. There was no evidence of necrotizing enterocolitis and the patient was NPO for a total of 5 days. Feedings were restarted slowly but the patient developed abdominal distention again. No other signs or symptoms were present at that time and the antibiotics were stopped on day of life 14 as two sets of blood cultures and CSF cultures from admission were negative. CBC and CRP were within normal limits. On day of life 16 the patient continued having feeding problems, had a temperature of 1018F, and lethargy. A sepsis workup was done. The CRP was 3.5 mg/dl (normal 0 to 0.8 mg/dl).The CBC was: 12,300 WBC, 41% neutrophils, 16 bands, 34 lymphocytes, and two sets of blood cultures were positive for S. cerevisiae. CSF and urine cultures were negative. A head ultrasound, echocardiogram, abdominal and renal ultrasound, and ophthalmologic evaluation were normal. Amphotericin B was started at 1 mg/kg per day and 26 days of treatment were completed. The patient started tolerating feedings at day of life 20 and remained asymptomatic afterwards. Blood cultures after 22 days of treatment remained negative. The only other problem the infant had was anemia due to prematurity and phlebotomy. She required three blood transfusions during her stay. The patient was discharged on full feeds on day of life 46.
DISCUSSION
Serious yeast infections have been associated with burns, antibiotic therapy, hyperalimentation, indwelling venous catheters, and prior surgery. There have been also some reports of infection secondary to oral ingestion of viable microorganisms in nutritional supplements. 4, 5 The English-language literature contains reports of 25 patients with opportunistic infections caused by S. cerevisiae. Three of those patients were children, and one was a premature 28-week-old neonate. The neonate and one of the children survived. They were both treated with amphotericin B for 30 days at 1 mg/kg per day. 6 The 28-week-old neonate had multiple underlying problems and congenital anomalies. The patient was on antibiotics and dexamethasone therapy for chronic lung disease. The patient also had central venous catheters and at 10 weeks of age he developed sepsis with positive blood cultures for S. cerevisiae and Klebsiella. The catheter was removed at that point and the infection did not recur. The patient who did not survive had a course complicated by infective endocarditis and unsuccessful attempts to establish central venous access. 6 It is clear that yeast infections are increasing. The increase can be ascribed to many factors, such as immunosuppressive therapeutic regimens, long-term catheterization, broad-spectrum antibiotic use, and longer survival of immunologicaly compromised individuals. Accompanying the increase in fungal infections is the recognition that yeast previously thought innocuous is capable of infecting humans. 2 Catheterization results in disruption of the integrity of the cutaneous barrier, antineoplastic agents cause thinning of the protective mucous barrier of the gastrointestinal tract and further attenuation of cellular immune function, and broad-spectrum antibiotics can lead to proliferation of yeast growth on mucosal surfaces. 2 In our patient the common risk factors with previous reports was immunosuppression (secondary to prematurity) and prior use of broad-spectrum antibiotics. The intestine would appear to be the likely site of colonization with compromised intestinal integrity secondary to the antibiotics, which could have predisposed to invasive infection. Due to the rarity of infections caused by this organism, it is unlikely that any prospective clinical data regarding diagnosis and treatment will ever be generated. 7 Optimal management of S. cerevisiae infections should include drainage of identified foci, removal of foreign bodies and administration of amphotericin B.
The majority of serious saccharomyces infections have been treated with amphotericin B, imidazoles and 5-fluorocytosine may be additive and/or synergistic. Until reliable sensitivity test are developed, amphotericin B should be the agent of choice for serious Saccharomyces infection. 7 
